Showing results (1801-1810 of 1,808) with videos related to
Sort By:
Pageof 181
You have reached the last page of results.This site can display upto 1,808 results.
Science (New York, N.Y.)|November 4, 2017
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsBertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, et al.Science (New York, N.Y.)|August 22, 2020
Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophageAurélie Fluckiger, Romain Daillère, Mohamed Sassi, et al.Cell Death and Differentiation|July 7, 2021
Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosisAnne-Gaëlle Goubet, Agathe Dubuisson, Arthur Geraud, et al.Nature Medicine|July 9, 2021
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeMiles C Andrews, Connie P M Duong, Vancheswaran Gopalakrishnan, et al.Proceedings of the National Academy of Sciences of the United States of America|June 23, 2010
Genome sequences of the human body louse and its primary endosymbiont provide insights into the permanent parasitic lifestyleEwen F Kirkness, Brian J Haas, Weilin Sun, et al.Research Square|January 19, 2022
The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodiesJeremy Manry, Paul Bastard, Adrian Gervais, et al.Proceedings of the National Academy of Sciences of the United States of America|May 16, 2022
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesJérémy Manry, Paul Bastard, Adrian Gervais, et al.Science Immunology|August 20, 2021
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deathsPaul Bastard, Adrian Gervais, Tom Le Voyer, et al.Pageof 181